CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. A large number of approvals for contrast agents
4.1.2. Increasing number of public & private diagnostic centres
4.1.3. The rise in prevalence of cancer and cardiovascular diseases
4.1.4. The surge in awareness about pre-diagnosis of diseases
4.1.5. Increase in the number of installations of imaging devices such as CT and MRIs around
the globe
4.2. Market Restraints & Challenges
4.2.1. Restriction and withdrawal of linear gadolinium-based contrast agents
4.2.2. Side effects and allergic reactions associated with contrast agents
4.2.3. Technological advancements in imaging solutions
CHAPTER 5. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET – BY
TYPE
5.1. Microbubble Contrast Media
5.2. Barium-Based Contrast Media
5.3. Iodinated Contrast Media
5.4. Gadolinium-Based Contrast Media
CHAPTER 6. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET – BY
MODALITY
6.1. Magnetic Resonance Imaging
6.2. Ultrasound
6.3. X-Ray/CT
CHAPTER 7. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET – BY
INDICATION
7.1. Musculoskeletal Disorders
7.2. Neurological Disorders
7.3. Nephrological Disorders
7.4. Cardiovascular Disorders
7.5. Cancer
7.6. Gastrointestinal Disorders
CHAPTER 8. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET - BY
ROUTE OF ADMINISTRATION
8.1. Oral
8.2. Rectal
8.3. Intravascular
8.4. Others
CHAPTER 9. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET – BY
APPLICATION
9.1. Radiology
9.2. Interventional Cardiology
9.3. Interventional Radiology
CHAPTER 10. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET - BY
GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.2.4. Costa Rica
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Chile
10.3.4. Columbia
10.3.5. Others
10.4. Europe
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Russia
10.4.7. Netherlands
10.4.8. Switzerland
10.4.9. Poland
10.4.10. Others
10.5. APAC
10.5.1. China
10.5.2. Japan
10.5.3. India
10.5.4. South Korea
10.5.5. Australia & New Zealand
10.5.6. Malaysia
10.5.7. Singapore
10.5.8. Others
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. Iran
10.6.4. Iraq
10.6.5. Qatar
10.6.6. South Africa
10.6.7. Algeria
10.6.8. Morocco
10.6.9. Nigeria
10.6.10. Egypt
10.6.11. Others
CHAP0TER 11. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET -
COMPANY PROFILES
11.1. Nanoscan Imaging, LLC.
11.2. Taejoon Pharm Co., Ltd.
11.3. CMC Contrast AB
11.4. Spago Nanomedical AB
11.5. Subhra Pharma, Pvt. Ltd.
11.6. Guerbet, LLC.
11.7. GE Healthcare
11.8. Sanochemia Pharmazeutika AG
11.9. Lantheus Medical Imaging, Inc.
11.10. Bracco Diagnostic, Inc.
11.11. General Electric Company
11.12. nanoPET Pharma GmbH
11.13. Bayer AG
CHAPTER 12. GLOBAL CONTRAST MEDIA/CONTRAST AGENTS MARKET –
COMPETITIVE LANDSCAPE
12.1. Market Share Analysis
12.2. Strategies adopted by top companies
12.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 13. MARKET INSIGHTS
13.1. Industry Experts Insights
13.2. Analysts Opinions
13.3. Investment Opportunities
CHAPTER 14. APPENDIX
14.1. List of Tables
14.2. List of Figures
